Compare Cronos Group Inc (CRON) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Meta Platforms Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Meta Platforms Inc trades at $721.74 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 1533.3× Cronos Group Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Meta Platforms Inc for 127 Days on average.
| CRON | META | |
|---|---|---|
Market Cap | $1.20B | $1.84T |
Volume | 450,387 | 12,743,601 |
Sector | Health | Media |
52-Week High | $3.55 | $777.59 |
52-Week Low | $2.30 | $525.72 |
Typical Hold Time | 22 Days | 127 Days |
Enterprise Value | $401.73M | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
Meta Platforms (META) trades at $720.89, down 2.43% on the day, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.8% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B partnership with CoreWeave highlight growth initiatives. Analyst consensus remains strongly bullish with 80% buy ratings and a $781 price target.
Meta presents a compelling investment case with strong profitability metrics and AI-driven growth potential, though faces regulatory risks from ongoing litigation and significant capital expenditure requirements. The stock's current valuation at 27x P/E appears reasonable given growth prospects, but investors should monitor execution on AI monetization and legal developments that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
